Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 70069-835

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 70069-835). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Somerset Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton_pemetrexed 100 mg (Carton 100 mg)

Carton_pemetrexed 100 mg (Carton 100 mg)
This text provides information about "Pemetrexed for Injection, USP," including its storage instructions, dosage details, and reconstitution process. The text also mentions the contents of each vial, the caution that it is a cytotoxic agent, and instructions for administration. Additionally, it includes the serialization details and mentions that it is for intravenous use only. The product is available in 100 mg/vial single-dose vials.*
FDA Label Image

Carton_pemetrexed 500 mg (Carton 500 mg)

Carton_pemetrexed 500 mg (Carton 500 mg)
This text provides important information about Pemetrexed, an injectable medication used for cancer treatment. It includes details such as dosage instructions, storage recommendations, reconstitution guidelines, and manufacturer information. The medication is a cytotoxic agent that requires cautious handling. Pemetrexed is available in vials containing 500 mg of the active ingredient. Users are advised to reconstitute the medication with 0.9% Sodium Chloride Injection and administer the solution within 24 hours. The text also contains the National Drug Code (NDC) for identification purposes and specifies that the medication is for IV use only.*
FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
This text lists various chemotherapy regimens: A+PHC includes Pemetrexed, Pembrolizumab, and platinum chemotherapy, while AVC consists of Pemetrexed, platinum chemotherapy, and a placebo. These regimens are potentially used for cancer treatment.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
This text appears to be a table showing survival time in months for patients at risk in two groups. One group is labelled "AC" and the other "GC". It includes data on the number of patients at risk for each time point.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
This text seems to be a survival analysis result comparing two treatments, Pemetrexed + Cisplatin (AC) and Gemcitabine + Cisplatin (GC), in terms of survival time in months. It shows the number of patients at risk for each treatment at different time points, along with the survival probabilities. The data includes survival probabilities, patient counts, and survival times at different intervals.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
This text provides survival probability data for two different treatments: IPemetrexed + Cisplatin (AC) and Gemcitabine + Cisplatin (GC). The data is presented over a period of 30 months, showing the survival time in months for patients under each treatment. The number of patients at risk is also indicated for both treatment groups at different time points.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
This text appears to show survival probabilities at different time points for two different groups of patients. It includes the number of patients at risk at each time point for the two groups, identified as "Pemewd" and "Pubo". The number of patients at risk decreases as time progresses, reflecting survival outcomes for each group.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
This section of text provides survival probability data for patients with Squamous NSCLC in Study JMEN. It includes a chart showing the Survival Time in months and the number of Patients at Risk at different time points. The Kaplan-Meier Curves are used to display the Overall Survival rates for the patients with this type of lung cancer.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
This data likely represents survival probability and time in months for two groups of patients: Pometexsd (359 patients at risk) and Placebo (180 patients at risk). The survival time varies from 0 to 166 months, with the number of patients at risk decreasing over time. This information can be used to analyze the effectiveness of the treatments on patient survival rates.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
FDA Label Image

Label_pemetrexed 100 mg (Label 100 mg)

Label_pemetrexed 100 mg (Label 100 mg)
This text provides details about a cytotoxic agent in a vial containing pemetroxed disodium. It mentions the amount of pemetrexed and mannitol in each vial. Instructions about adjusting pH with hydrochloric acid or sodium hydroxide, storage conditions, and dosage information are also included. The manufacturer is Somerset Therapeutics, LLC, and the product is intended for intravenous use. Additional details such as storage temperature and code number are provided as well.*
FDA Label Image

Label_pemetrexed 500 mg (Label 500 mg)

Label_pemetrexed 500 mg (Label 500 mg)
This text provides important information about a cytotoxic agent in the form of pemetrexed disodium, stored as a powder in vials containing 500 mg. The ingredients include pemetrexed, mannitol, and may include hydrochloric acid or sodium hydroxide for pH adjustment. It specifies storage conditions and recommendations for storage temperature, with instructions to discard any unused portion. The manufacturing details are also provided, showing that the product is made for Somerset Therapeutics, LLC in India.*
FDA Label Image

Structural Formula (Pemetrexed F01 V01)

Structural Formula (Pemetrexed F01 V01)
FDA Label Image

Table 11 (Table 11)

Table 11 (Table 11)
FDA Label Image

Table-12 (Table 12)

Table-12 (Table 12)
This is a statistical analysis of different histologic subgroups in Non-Small Cell Lung Cancer (NSCLC) patients treated with Cisplatin. The data includes median survival times, hazard ratios, and confidence intervals for various subtypes such as Adenocarcinoma, Large Cell, Non-squamous, Squamous Cell, amongst others. The analysis is adjusted for factors like ECOG PS, gender, disease stage, and pathological diagnosis basis. The study provides valuable insights into the survival outcomes of these subgroups in response to Cisplatin treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.